ArchiveSeptember 2010

Oral Cladribine turned down by the European Medicines Agency

Despite evidence that oral cladribine is effective in relapsing-remitting MS the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion regarding the marketing authorization for Cladribine Tablets. The CHMP have concerns about the long-term safety of Cladribine. In my opinion, long-term safety data can only be obtained from post...

Fingolimod – first oral drug for MS in the United States

The FDA has licensed Fingolimod as a first-line therapy for people with relapsing-remitting MS. Let’s hope it passes through the European Medicine Agency (EMA) with the same ease as the FDA and NICE gives it the thumbs up in the UK; the pessimist in me expects not. I predict that its use will be handcuffed in Europe for patients with highly-active disease (similar to Natalizumab) and for...

Vince Cable’s “Science, Research and Innovation” Speech

Apologies about politicising this blog, but what happens to investment in science in the UK will eventually impact on the lives of people with MS and their families. The only way to limit the impact of this devastating disease is through scientific research. The unmet need in MS is massive: 1. We have yet to optimise disease-modifying therapies. Is expecting a cure too much? 2. What about...

No association between allergies and multiple sclerosis

Different types of inflammation are defined by immunologists by the type of cells and the mediators used by these cells. The current dogma: inflammation in MS is mediated by either T-helper one (Th1) or T-helper 17 (Th17) cells. In comparison, allergies are due to a T-helper two (Th2) immune response, which may be protective in MS. A large analysis of all published studies on allergic disease and...

Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis

Does low does naltrexone (LDN) improve quality of life in PwMS? A study in 80 PwMS was performed to evaluate the effect of 8 weeks of treatment with LDN (4.5mg taken at night). Although LDN was associated with significant improvement in some mental health quality of life measures, the trial was too small to draw definitive conclusions. Interpretation: this study was too small to be definitive...

Translate

Categories

Recent Posts

Recent Comments

Archives